Lymph node metastases and recurrence in pT1 colorectal cancer: Prediction with the International Budding Consortium Score-A retrospective, multi-centric study.

CRC colorectal cancer early grade histology lymph node metastases lymphovascular invasion pT1 prediction recurrence

Journal

United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807

Informations de publication

Date de publication:
09 Jan 2024
Historique:
received: 26 05 2023
accepted: 03 11 2023
medline: 9 1 2024
pubmed: 9 1 2024
entrez: 9 1 2024
Statut: aheadofprint

Résumé

The International Collaboration on Cancer Reporting proposes histological tumour type, lymphovascular invasion, tumour grade, perineural invasion, extent, and dimensions of invasion as risk factors for lymph node metastases and tumour progression in completely endoscopically resected pT1 colorectal cancer (CRC). The aim of the study was to propose a predictive and reliable score to optimise the clinical management of endoscopically resected pT1 CRC patients. This multi-centric, retrospective International Budding Consortium (IBC) study included an international pT1 CRC cohort of 565 patients. All cases were reviewed by eight expert gastrointestinal pathologists. All risk factors were reported according to international guidelines. Tumour budding and immune response (CD8+ T-cells) were assessed with automated models using artificial intelligence. We used the information on risk factors and least absolute shrinkage and selection operator logistic regression to develop a prediction model and generate a score to predict the occurrence of lymph node metastasis or cancer recurrence. The IBC prediction score included the following parameters: lymphovascular invasion, tumour buds, infiltration depth and tumour grade. The score has an acceptable discrimination power (area under the curve of 0.68 [95% confidence intervals (CI) 0.61-0.75]; 0.64 [95% CI 0.57-0.71] after internal validation). At a cut-off of 6.8 points to discriminate high-and low-risk patients, the score had a sensitivity and specificity of 0.9 [95% CI 0.8-0.95] and 0.26 [95% 0.22, 0.3], respectively. The IBC score is based on well-established risk factors and is a promising tool with clinical utility to support the management of pT1 CRC patients.

Sections du résumé

BACKGROUND BACKGROUND
The International Collaboration on Cancer Reporting proposes histological tumour type, lymphovascular invasion, tumour grade, perineural invasion, extent, and dimensions of invasion as risk factors for lymph node metastases and tumour progression in completely endoscopically resected pT1 colorectal cancer (CRC).
OBJECTIVE OBJECTIVE
The aim of the study was to propose a predictive and reliable score to optimise the clinical management of endoscopically resected pT1 CRC patients.
METHODS METHODS
This multi-centric, retrospective International Budding Consortium (IBC) study included an international pT1 CRC cohort of 565 patients. All cases were reviewed by eight expert gastrointestinal pathologists. All risk factors were reported according to international guidelines. Tumour budding and immune response (CD8+ T-cells) were assessed with automated models using artificial intelligence. We used the information on risk factors and least absolute shrinkage and selection operator logistic regression to develop a prediction model and generate a score to predict the occurrence of lymph node metastasis or cancer recurrence.
RESULTS RESULTS
The IBC prediction score included the following parameters: lymphovascular invasion, tumour buds, infiltration depth and tumour grade. The score has an acceptable discrimination power (area under the curve of 0.68 [95% confidence intervals (CI) 0.61-0.75]; 0.64 [95% CI 0.57-0.71] after internal validation). At a cut-off of 6.8 points to discriminate high-and low-risk patients, the score had a sensitivity and specificity of 0.9 [95% CI 0.8-0.95] and 0.26 [95% 0.22, 0.3], respectively.
CONCLUSION CONCLUSIONS
The IBC score is based on well-established risk factors and is a promising tool with clinical utility to support the management of pT1 CRC patients.

Identifiants

pubmed: 38193866
doi: 10.1002/ueg2.12521
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Swiss Cancer Society
ID : KFS-4108-02-2017
Organisme : Dutch Cancer Society
ID : KWF KUN2017-10602

Informations de copyright

© 2024 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.

Références

Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, et al. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) colon cancer V2 Oct 27,2022; 2022. [cited Dec 08 2022].
Argiles G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291-1305. https://doi.org/10.1016/j.annonc.2020.06.022
International Union against Cancer. Committee on TNM Classification. TNM classfication of malignant tumors. 8 ed. 2017.
Nagtegaal IOR. Colorectal adenocarcinomas. In: WHO classification of tumours editorial board. Digestive system tumours [internet]. Lyon: International Agency for Research on Cancer; 2019 [2022 Dec 20]. (WHO classification of tumours series, 5th ed.; vol. 1). https://tumourclassification.iarc.who.int/chapters/31
Loughrey MBAM, Brown I, et al. Colorectal cancer histopathology reporting guide. Sydney: International Collaboration on Cancer Reporting; 2020. ISBN: 978-1-922324-01-6.
Nivatvongs S, Rojanasakul A, Reiman HM, Dozois RR, Wolff BG, Pemberton JH, et al. The risk of lymph node metastasis in colorectal polyps with invasive adenocarcinoma. Dis Colon Rectum. 1991;34(4):323-328. https://doi.org/10.1007/BF02050592
Kikuchi R, Takano M, Takagi K, Fujimoto N, Nozaki R, Fujiyoshi T, et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. Dis Colon Rectum. 1995;38(12):1286-1295. https://doi.org/10.1007/BF02049154
Backes Y, Elias SG, Groen JN, Schwartz MP, Wolfhagen FH, Geesing JM, et al. Histologic factors associated with need for surgery in patients with pedunculated T1 colorectal carcinomas. Gastroenterology. 2018;154(6):1647-1659. https://doi.org/10.1053/j.gastro.2018.01.023
Ueno H, Mochizuki H, Hashiguchi Y, Shimazaki H, Aida S, Hase K, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology. 2004;127(2):385-394. https://doi.org/10.1053/j.gastro.2004.04.022
Pimentel-Nunes P, Libanio D, Bastiaansen BAJ, Bhandari, P, Bisschops, R, Bourke, MJ, et al. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European society of gastrointestinal endoscopy (ESGE) guideline - update 2022. Endoscopy 2022; 54(06): 591-622. 20220506. https://doi.org/10.1055/a-1811-7025
Vermeer NCA, Backes Y, Snijders HS, Bastiaannet E, Liefers GJ, Moons LMG, et al. National cohort study on postoperative risks after surgery for submucosal invasive colorectal cancer. BJS Open. 2019;3(2):210-217. https://doi.org/10.1002/bjs5.50125
Zwager LW, Bastiaansen BAJ, Montazeri NSM, Hompes R, Barresi V, Ichimasa K, et al. Deep submucosal invasion is not an independent risk factor for lymph node metastasis in T1 colorectal cancer: a meta-analysis. Gastroenterology. 2022;163(1):174-189. https://doi.org/10.1053/j.gastro.2022.04.010
Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30(9):1299-1311. https://doi.org/10.1038/modpathol.2017.46
Lugli A, Zlobec I, Berger MD, Kirsch R, Nagtegaal ID. Tumour budding in solid cancers. Nat Rev Clin Oncol. 2021;18(2):101-115. https://doi.org/10.1038/s41571-020-0422-y
Rogers AC, Winter DC, Heeney A, Gibbons D, Lugli A, Puppa G, et al. Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. Br J Cancer. 2016;115(7):831-840. https://doi.org/10.1038/bjc.2016.274
Cappellesso R, Luchini C, Veronese N, Lo Mele M, Rosa-Rizzotto E, Guido E, et al. Tumor budding as a risk factor for nodal metastasis in pT1 colorectal cancers: a meta-analysis. Hum Pathol. 2017;65:62-70. https://doi.org/10.1016/j.humpath.2017.04.013
Dykstra MA, Gimon TI, Ronksley PE, Buie WD, MacLean AR. Classic and novel histopathologic risk factors for lymph node metastasis in T1 colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum. 2021;64(9):1139-1150. https://doi.org/10.1097/DCR.0000000000002164
Ebbehoj AL, Jorgensen LN, Krarup PM, Smith HG. Histopathological risk factors for lymph node metastases in T1 colorectal cancer: meta-analysis. Br J Surg. 2021;108(7):769-776. https://doi.org/10.1093/bjs/znab168
Pages F, Andre T, Taieb J, Vernerey D, Henriques J, Borg C, et al. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. Ann Oncol. 2020;31(7):921-929. https://doi.org/10.1016/j.annonc.2020.03.310
Idos GE, Kwok J, Bonthala N, Kysh L, Gruber SB, Qu C. The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: a systematic review and meta-analysis. Sci Rep. 2020;10(1):3360. https://doi.org/10.1038/s41598-020-60255-4
Oshi M, Sarkar J, Wu R, et al. Intratumoral density of regulatory T cells is a predictor of host immune response and chemotherapy response in colorectal cancer. Am J Cancer Res. 2022;12:490-503.
Lugli A, Karamitopoulou E, Panayiotides I, Karakitsos P, Rallis G, Peros G, et al. CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer. Br J Cancer. 2009;101(8):1382-1392. https://doi.org/10.1038/sj.bjc.6605318
Dawson H, Christe L, Eichmann M, Reinhard S, Zlobec I, Blank A, et al. Tumour budding/T cell infiltrates in colorectal cancer: proposal of a novel combined score. Histopathology. 2020;76(4):572-580. https://doi.org/10.1111/his.14006
Nearchou IP, Lillard K, Gavriel CG, Ueno H, Harrison DJ, Caie PD. Automated analysis of lymphocytic infiltration, tumor budding, and their spatial relationship improves prognostic accuracy in colorectal cancer. Cancer Immunol Res. 2019;7(4):609-620. https://doi.org/10.1158/2326-6066.CIR-18-0377
Bokhorst JM, Nagtegaal ID, Zlobec I, Dawson H, Sheahan K, Simmer F, et al. Semi-supervised learning to automate tumor bud detection in cytokeratin-stained whole-slide images of colorectal cancer. Cancers (Basel). 2023;15(7):2079. https://doi.org/10.3390/cancers15072079
Swiderska-Chadaj Z, Pinckaers H, van Rijthoven M, Balkenhol M, Melnikova M, Geessink O, et al. Learning to detect lymphocytes in immunohistochemistry with deep learning. Med Image Anal. 2019;58:101547. ARTN 101547. https://doi.org/10.1016/j.media.2019.101547
Studer LBJ, Zlobec I, et al. Validation of computer-assisted tumour-bud and T-cell detection in pT1 colorectal cancer. In: ECP glasgow. Springer; 2020. p. S37. (online).
Janssen KJ, Siccama I, Vergouwe Y, Koffijberg H, Debray T, Keijzer M, et al. Development and validation of clinical prediction models: marginal differences between logistic regression, penalized maximum likelihood estimation, and genetic programming. J Clin Epidemiol. 2012;65(4):404-412. https://doi.org/10.1016/j.jclinepi.2011.08.011
Mehta HB, Mehta V, Girman CJ, Adhikari D, Johnson ML. Regression coefficient-based scoring system should be used to assign weights to the risk index. J Clin Epidemiol. 2016;79:22-28. https://doi.org/10.1016/j.jclinepi.2016.03.031
Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Br J Surg. 2015;102(3):148-158. https://doi.org/10.1002/bjs.9736
Cracco N, Todaro V, Pedrazzi G, Del Rio P, Haboubi N, Zinicola R. The risk of lymph node metastasis in T1 colorectal cancer: new parameters to assess the degree of submucosal invasion. Int J Colorectal Dis. 2021;36(1):41-45. https://doi.org/10.1007/s00384-020-03738-0
Bokhorst JM, Blank A, Lugli A, Zlobec I, Dawson H, Vieth M, et al. Assessment of individual tumor buds using keratin immunohistochemistry: moderate interobserver agreement suggests a role for machine learning. Mod Pathol. 2020;33(5):825-833. https://doi.org/10.1038/s41379-019-0434-2
Aizawa D, Sugino T, Oishi T, Hotta K, Imai K, Shiomi A, et al. The essential problem of over-measuring the depth of submucosal invasion in pT1 colorectal cancer. Virchows Arch. 2022;480(2):323-333. https://doi.org/10.1007/s00428-021-03221-3
Kajiwara Y, Oka S, Tanaka S, Nakamura T, Saito S, Fukunaga Y, et al. Nomogram as a novel predictive tool for lymph node metastasis in T1 colorectal cancer treated with endoscopic resection: a nationwide, multicenter study. Gastrointest Endosc. 2023;97(6):1119-1128.e5. https://doi.org/10.1016/j.gie.2023.01.022
Griggs RK, Novelli MR, Sanders DS, Warren BF, Williams GT, Quirke P, et al. Challenging diagnostic issues in adenomatous polyps with epithelial misplacement in bowel cancer screening: 5 years' experience of the Bowel Cancer Screening Programme Expert Board. Histopathology. 2017;70(3):466-472. https://doi.org/10.1111/his.13092
Cappellesso R, Nicole L, Zanco F, Lo Mele M, Fassina A, Ventura L, et al. Synchronous nodal metastatic risk in screening detected and endoscopically removed pT1 colorectal cancers. Pathol Res Pract. 2020;216(6):152966. https://doi.org/10.1016/j.prp.2020.152966

Auteurs

Heather Dawson (H)

Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.

John-Melle Bokhorst (JM)

Department of Pathology, Radboudumc, Nijmegen, the Netherlands.

Linda Studer (L)

Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
Institute of Artificial Intelligence and Complex Systems, University of Applied Sciences and Arts Western Switzerland, Fribourg, Switzerland.

Michael Vieth (M)

Institute of Pathology, Friedrich-Alexander-University Erlangen-Nuremberg, Klinikum Bayreuth, Bayreuth, Germany.

Ayse Selcen Oguz Erdogan (AS)

Department of Pathology, Radboudumc, Nijmegen, the Netherlands.

Sonay Kus Öztürk (S)

Department of Pathology, Radboudumc, Nijmegen, the Netherlands.

Richard Kirsch (R)

Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.

Scarlett Brockmoeller (S)

Pathology and Data Analytics, Leeds Institute of Medical Research at St. James's School of Medicine, Leeds, UK.

Gieri Cathomas (G)

Institute of Pathology, Kantonsspital Baselland, Liestal, Switzerland.

Rolf Buslei (R)

Institut und Praxis für Pathologie, Neuropathologie, Molekulare Diagnostik und Zytologie, Sozialstiftung Bamberg, Bamberg, Germany.

David Fink (D)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA.

Marie Roumet (M)

Clinical Trials Unit, University of Bern, Bern, Switzerland.

Inti Zlobec (I)

Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.

Jeroen van der Laak (J)

Department of Pathology, Radboudumc, Nijmegen, the Netherlands.

Iris D Nagtegaal (ID)

Department of Pathology, Radboudumc, Nijmegen, the Netherlands.

Alessandro Lugli (A)

Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.

Classifications MeSH